Hematology
Latest News
Obe-Cel Outcomes by Age; Brexu-Cel Expansion as a Predictor of Relapse-Free Survival in R/R ALL
July 30th 2025
Obecabtagene autoleucel (obe-cel) is shown to be effective and safe for older adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL), while brexucabtagene autoleucel's (brexu-cel) expansion predicts durable remission.
Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology
Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.
